Completed PHASE2 INTERVENTIONAL 1-arm NCT02098278

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Chylomicronemia

Sponsor: Catabasis Pharmaceuticals

Conditions Chylomicronemia, Familial Hyperlipoproteinemia Type I Hypertriglyceridemia Lipoprotein Lipase Deficiency, Familial

Interventions CAT-2003 Placebo

Updated 8 times since 2017 Last updated: Jul 19, 2016 Started: Mar 31, 2014 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chylomicronemia, Familial and Hyperlipoproteinemia Type I and is currently completed. Catabasis Pharmaceuticals leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catabasis Pharmaceuticals

Data source: Catabasis Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicoutimi, Canada
• Québec, Canada